Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Photocure
PHOPhotocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway. Address: Hoffsveien 4, Oslo, Norway, 0275
Analytics
Precio Objetivo de WallStreet
1 084.63 NOKRelación P/E
114.6809Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave PHO
Análisis de dividendos PHO
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout PHO
Valoración de la acción PHO
Finanzas PHO
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |